The first author, Michael C. Henderson, was a founder and served as Chairman of Albina Community Bank from 1995 until he retired at the end of 2009. He first learned about idiopathic pulmonary fibrosis (IPF) at the age of 58, when he was told that he had the disease. Ten years later, Mr. Henderson reflects on his passage through IPF in this personal narrative written with the assistance of Daniel M. Rose, Chief Executive Officer of the Pulmonary Fibrosis Foundation.
Imagine being told that you have a disease you have never heard of, a disease with no known cause for which there is no effective medical treatment and no cure. Your future has been instantly shortened to 3-5 years. I would like to share with you the story of how I was diagnosed with idiopathic pulmonary fibrosis (IPF), the progression of my disease and its impact on me, the difficult decisions I have made along the way, and how I am working to help others who have been afflicted with this disease.
My Symptoms before Diagnosis
In October 2003, I attended a business conference at Squaw Valley, California, elevation 6,500 ft (1,980 m) above sea level. I took a break for my daily walk and found myself gasping for air. For the rest of the meeting, I found myself stopping to catch my breath any time I exerted myself. This was definitely not normal for me. At home in Portland, Oregon, I had been walking a few miles a day on a regular basis without experiencing shortness of breath.
I knew something was wrong. Looking back, I recall similar episodes dating back 3 years in which I had comparable symptoms at elevation while skiing or hiking. My doctors attributed my symptoms to coronary artery disease or asthma. So, with a new stent and an inhaler, I began cardiac rehabilitation in January 2004.
My Diagnosis
I thank God for a cardiac rehab nurse who pulled me aside after a few weeks and said, "Your oxygen saturation is dropping too low and we don't think it is asthma or heart disease. You really should see a pulmonologist."
In June, a pulmonary physician diagnosed me with IPF. He said there was no effective treatment and no cure, and that I should get my affairs in order. He told me that I had no more than 3-5 years to live. That's it. That was the message.
Talk about a shock-try telling that to your wife and family! My whole world turned upside down that day. not walk across the parking lot without stopping to catch my breath. I tried walking up a short trail that had a slight grade. I failed that test. In November, we decided to knock a few things off my bucket list and took a road trip that included Bryce and Zion National Parks in Utah. We didn't even think about the elevation. It was spectacular, but I had to view some of it through Donna's eyes. If it was a long walk or uphill to see the sights, she went, came back, and told me how spectacular it was.
It's a good thing I'm not one who gets depressed easily. That could have done it. I was no longer in control.
By the time I saw Dr. Raghu in December 2004, my shortness of breath at sea level was not too bad, but was slowly getting worse.
By March 2005, I needed oxygen at night and for exercise, which helped greatly. I bought a pulse oximeter to manage my exercise.
By April, my deterioration began to accelerate. Without oxygen, a slight grade became difficult and stairs were a killer. I put together a backpack of oxygen and continued to exercise almost daily at a cardiac rehab program. With 2 L of oxygen I was able to walk a few miles. I felt good physically. I even took a fishing trip in May with my brother-in-law. We took 42 tanks of oxygen and I used them all.
The symptoms were not what I expected. Shortness of breath seemed to be a real problem with quick movements, like getting up to walk across the room. If I moved slowly at first, I didn't get short of breath. If I moved quickly, I did. I could feel the deterioration in lung function. For me it was a stair-step effect. It might be a few months or only a few weeks, but the decrease was noticeable. Sure enough, the pulmonary laboratory would confirm the impairment.
What about the Cough?
In July 2004, I went on a fishing trip in Canada. It's my first memory that cough was becoming an issue. I remember being yelled at by one member of the group-a first class "jerk."
He was very irritated by the continuous clearing of my throat. It happened about every 30 seconds. Good thing we didn't share a tent.
For some people, the cough is the worst part. It is absolutely debilitating. I never had it that bad. It was more a constant clearing of my throat, just plain irritating to me and to those around me. I only coughed when speaking or out of breath.
Treatment Options
I did a lot of homework on treatment for IPF. The most interesting possibilities to me were imatinib, IFN-g1b, and pirfenidone. I spoke with Dr. Brian Drucker at University of Oregon Health Sciences Center about imatinib. Treatment with that drug required a move to Minnesota to be at the Mayo Clinic. I saw the data on the Japanese pirfenidone trial and was very enthused. Imagine: a pill that might stop the disease from progressing. However, it was unavailable in the United States. The University of Washington was conducting a clinical trial of IFN-g1b, which had shown some promise. A friend suggested I visit John of God in Brazil. I was desperate. I would have done anything and gone almost anywhere to find a cure.
In March 2005, Dr. Raghu and I discussed the only practical treatment options: do nothing; try the IPF cocktail of prednisone, azathioprine, and N-acetyl cysteine (NAC); or participate in a clinical trial. The only promising trial available locally was IFN-g1b, and Dr. Raghu strongly encouraged me to participate. My research told me that it was also available off label, so I asked him to consider that as an option. He laid out the pros and cons of all the options and left the choice to me. So, after careful thought and some more research, I chose a course of prednisone, NAC, and IFN-g1b. I wanted to make sure I was actually getting IFN-g1b. I understood the value of the clinical trial, but if I could know that I was actually on the drug, I would find some other way to give back to the research effort. The IFN-g1b trial was terminated shortly after I made my decision, so we went on the IPF cocktail (prednisone, azathioprine, and NAC).
Continued Disease Progression
By the fall of 2005, speaking became more difficult. My voice was softer and I coughed frequently. I could still walk slowly around town with 2 L of oxygen, but everything became more difficult. Showers were the worst. They were exhausting. Bending over to tie my shoes became a challenge. I became more sedentary. I still went to work every day, but put in less time.
By December, I was on oxygen 24/7, otherwise I would be out of breath before I reached the bathroom.
How IPF Changed My Life
When I look back, I realize that IPF changed everything. Physically, I would walk instead of run; I avoided hills and stairs; I did not feel like exercising; I tired easily; and I lost my appetite. I couldn't do the things I wanted to do: fishing, hiking, and traveling. I ended up in a wheelchair at times. My life changed socially, I avoided crowds and parties, and my friends went to fun places without me. I became self-conscious, my cough irritated those around me, and the sound of the oxygen concentrator irritated people nearby. People shied away from me, they were afraid of what I had. One of my IPF friends had an incident in an elevator. He said, "Don't worry, it's not contagious; it's just terminal."
The impact on my family was profound. My wife was stressed out and my kids were unsure of how to respond.
The mental aspects were quite difficult. At times I became depressed, which was very unlike me. I was angry. I got tired of answering "How are you feeling?" When one can't breathe, one can't think. I became fearful: will I be able to keep my job? Will I run out of oxygen? Can I fly? Can I go on a cruise? One begins to wonder: will my sibling or kids get IPF? What is it like at the end?
The Lung Transplant The Foundation is involved in many activities to help improve the quality of life for the patients, family members, and caregivers impacted by pulmonary fibrosis. Presently, we are implementing the PFF Patient Registry and the PFF Care Center Network that will standardize and improve the care patients receive. In addition, the Network should increase the efficiency for patient enrollment in clinical trials. Finally, they will attempt to coordinate multicenter research through public and private partnerships.
The Foundation hosts and supports a number of educational activities. We held our biennial international conference, PFF Summit: from Bench to Bedside in La Jolla, California in December 2013. This event was attended by over 500 individuals, and included patients, caregivers, healthcare professionals, industry and government representatives, and members of the financial community. The Foundation has assisted in the presentation of local educational events as well as similar events in the EU.
The PFF is closely involved with expansion of the patient support group network, including both in-person and online meetings. We have held support group leader workshops in the United States and European Union, and are creating a U.S. and International Patient Advisory Council to enhance the communication between the patient community and the Foundation.
I have been involved in the planning and implementation of many of these activities. They have been personally rewarding and, even more importantly, have served as a way for me to give back to those who have so generously supported me. As an active member of the IPF and transplant communities, I am contacted almost weekly by newly diagnosed patients and their families. It is such an honor to share my experience with others, and I hope that my success story makes them feel less alone and more hopeful. Although the hardest part of my involvement is attending memorials of friends, their passing also highlights the importance of my work with the Foundation and the urgent, critical need for a cure. n Author disclosures are available with the text of this article at www.atsjournals.org.
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